国金证券：长效AD产品价值进一步获得MNC验证维持康诺亚-B(02162)“买入”评级

智通财经06-23

智通财经APP获悉，国金证券发布研报称，2026年6月22日，艾伯维宣布拟以约109亿美金收购Apogee公司，其核心产品为长效IL-13单抗APG777，该交易预计于2026Q3完成。康诺亚同赛道药物CM512有望支持3-6个月给药间隔，目前正开展AD、COPD等多适应症II期。该行预测公司2026-2028年收入分别为28.71/20.64/29.94亿元，同比+300.8%/-28.1%/+...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2645600470?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-23 10:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645600470","market":"us","top_or_hot":-1,"title":"国金证券：长效AD产品价值进一步获得MNC验证 维持康诺亚-B(02162)“买入”评级","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，国金证券发布研报称，2026年6月22日，艾伯维宣布拟以约109亿美金收购Apogee公司，其核心产品为长效IL-13单抗APG777，该交易预计于2026Q3完成。康诺亚同赛道药物CM512有望支持3-6个月给药间隔，目前正开展AD、COPD等多适应症II期。该行预测公司2026-2028年收入分别为28.71/20.64/29.94亿元，同比+300.8%/-28.1%/+...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1457341.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国金证券：长效AD产品价值进一步获得MNC验证 维持康诺亚-B(02162)“买入”评级</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国金证券：长效AD产品价值进一步获得MNC验证 维持康诺亚-B(02162)“买入”评级\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-23 10:42 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1457341.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，国金证券发布研报称，2026年6月22日，艾伯维宣布拟以约109亿美金收购Apogee公司，其核心产品为长效IL-13单抗APG777，该交易预计于2026Q3完成。康诺亚同赛道药物CM512有望支持3-6个月给药间隔，目前正开展AD、COPD等多适应症II期。该行预测公司2026-2028年收入分别为28.71/20.64/29.94亿元，同比+300.8%/-28.1%/+...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1457341.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1457341.html","article_id":"2645600470","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645600470","pubTimestamp":1782182527,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"长效AD产品价值或将进一步获MNC验证AD患者治疗周期长、复发率高，疗效和给药便利性对患者而言至关重要，因此在疗效接近或具备非劣基础上，若能实现更低频给药，产品有望在维持治疗和商业化竞争中形成明显优势。Apogee的IL-13长效抗体获得MNC艾伯维青睐，说明MNC对长效AD资产的战略价值和峰值销售潜力给予厚望，长效AD产品价值进一步获得MNC验证。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"02162":"康诺亚-B","AD":"Array Digital Infrastructure Inc."},"translate_title":"Guojin Securities: Long-lasting AD Product Value Further Verified by MNC Maintains \"Buy\" Rating of Connoya-B (02162)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1.5,"AD":1.5},"content_text":"智通财经APP获悉，国金证券发布研报称，2026年6月22日，艾伯维宣布拟以约109亿美金收购Apogee公司，其核心产品为长效IL-13单抗APG777，该交易预计于2026Q3完成。康诺亚同赛道药物CM512有望支持3-6个月给药间隔，目前正开展AD、COPD等多适应症II期。该行预测公司2026-2028年收入分别为28.71/20.64/29.94亿元，同比+300.8%/-28.1%/+45.0%;净利润10.98/-5.01/3.44亿元，对应EPS分别为3.67/-1.68/1.15元，维持“买入”评级。国金证券主要观点如下：事件分析Apogee核心管线为长效IL-13单抗APG777，给药间隔可超延长至3-6个月。APG777目前针对2型炎症反应积极探索特异性皮炎AD、哮喘和嗜酸性食管炎三大适应症，进度最快的AD正处于临床II期阶段，计划于26H2启动III期临床。APG777核心亮点为其给药间隔可以拉长，且能维持较好的疗效，其于2026年6月披露了最新的II期Part-B数据，诱导期给药间隔为：W02针，W22针，W41针，W121针后3个月/6个月给药。16周数据显示，中剂量组在EASI-75相对安慰剂提升约41.9%，EASI-90提升约37.8%。相较于Dupixent的36.8%和25.8%非头对头对比下更优。长效AD产品价值或将进一步获MNC验证AD患者治疗周期长、复发率高，疗效和给药便利性对患者而言至关重要，因此在疗效接近或具备非劣基础上，若能实现更低频给药，产品有望在维持治疗和商业化竞争中形成明显优势。Apogee的IL-13长效抗体获得MNC艾伯维青睐，说明MNC对长效AD资产的战略价值和峰值销售潜力给予厚望，长效AD产品价值进一步获得MNC验证。康诺亚同赛道药物CM512有望支持3-6个月给药间隔，目前正开展AD、COPD等多适应症II期公司核心管线CM512(IL-13/TSLP双抗)同样靶向2型炎症反应疾病，半衰期约70天，有望支持3-6个月的给药间隔，预计近期将读出II期CRSwNP数据，26H2启动鼻窦炎III期临床，哮喘、COPDII期中期分析。若临床数据可支持延长给药间隔，其长效优势有望显著提升其市场竞争力。除了CM512外，公司年内仍有多项催化：CMG901预计于26H2递交中美NDA，CDH17 ADC预计于2026ESMO上披露I期数据，BCMAxCD3双抗预计于26H2递交轻链型淀粉样变性NDA。风险提示销售不及预期风险，研发进度不及预期，新药研发失败风险","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645600470","isCrawlerRequest":true}

国金证券：长效AD产品价值进一步获得MNC验证 维持康诺亚-B(02162)“买入”评级

精彩评论

国金证券：长效AD产品价值进一步获得MNC验证维持康诺亚-B(02162)“买入”评级